Clinical Trial Update: Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether fluvastatin 40 mg twice daily prevents graft vasculopathy in de novo renal transplant recipients; the study is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Vasculopathy

Drugs mentioned

• Fluvastatin (fluvastatin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graft Vasculopathy | Phase 4 | Status: COMPLETED